LY-503,430

LY-503,430

LY-503,430
Systematic (IUPAC) name
4'-{(1S)-1-fluoro-2-[(isopropylsulfonyl)amino]-1-methylethyl}-N-methylbiphenyl-4-carboxamide
Clinical data
Legal status
  • Investigational New Medicine
Routes of
administration
oral
Identifiers
CAS Registry Number  YesY
Synonyms LY-503,430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide
Chemical data
Formula C20H25FN2O3S
Molecular mass 392.49 g/mol
 YesY   

LY-503,430 is an ampakine drug developed by Eli Lilly.[1]

LY-503,430 produces both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP and also increasing levels of the neurotrophic factor BDNF in the brain, particularly in the substantia nigra, hippocampus and striatum.[2][3] It is orally active and the main application it is currently being developed for is treatment of Parkinson's Disease although it has also been proposed to be useful in the treatment of Alzheimer's Disease, depression and schizophrenia.[4][5]

References

  1. ^
  2. ^
  3. ^
  4. ^
  5. ^